rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Balchem Corporation

BCPC · Nasdaq

MaterialsChemicalsAbove a falling average

BCPC stood above a rising 150-day average in 23 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 1.6% above that average now. Chemicals: 24% of its 85 stocks in an uptrend (−5 points in four weeks); Materials: 18% (−6 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 6
Industry in uptrend
24% -5 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$2.3M
Officials’ trades on record
18

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.

17 Apr – 16 Oct
18%38%59%Apr 26Jun 26Jul 26Sep 26Oct 26

Chemicals: A minority of its stocks are in an uptrend and the share has been slipping. Materials: Few of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

18 disclosed lines: House 12, Senate 1, executive 5; 7 people.

WhoDidAmountTraded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k17 Sep 2026filed 12 Oct 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$50k–$100k29 Jul 2026filed 22 Sep 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k10 Jul 2026filed 4 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k15 May 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k30 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k30 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$50k–$100k4 Mar 2026filed 14 May 2026
Josh Gottheimer House: U.S. House ClerkNJ05soldjoint$1k–$15k9 Apr 2025filed 14 May 2025
Josh Gottheimer House: U.S. House ClerkNJ05sold$1k–$15k2 Dec 2021filed 10 Jan 2022
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k21 May 2020filed 16 Jun 2020
Donna E. Shalala House: U.S. House ClerkFL27sold$1k–$15k24 Jun 2019filed 27 Apr 2020
James B. Renacci House: U.S. House ClerkOH16sold$1k–$15k21 Aug 2018filed 5 Sep 2018

Insiders

Buy orders, 12 months0
Sale orders, 12 months3
Buyers · sellers0 · 3

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

Gilbert Ray Cisneros, Jr. HouseCA31 · last 17 Sep 20263 · 0
Donald J. Trump Executive branchWhite House Office · last 29 Jul 20262 · 3
Carl Martin Bengtsson Company insiderEVP & Chief Financial Officer · last 12 Feb 20260 · 0
Frederic Boned Company insiderSVP/GM, Human Nutri. & Health · last 12 Feb 20260 · 0
Hatsuki Miyata Company insiderEVP, CLO, & Secretary · last 12 Feb 20260 · 0
Job Leonard van Gunsteren Company insiderSVP and GM, Specialty Products · last 12 Feb 20260 · 6
Martin Luther Reid Company insiderSVP Chief Supply Chain Officer · last 12 Feb 20260 · 1
Michael Brent Tignor Company insiderSVP & Chief HR Officer · last 12 Feb 20260 · 1
Theodore L. Harris Company insiderChairman, President & CEO · last 12 Feb 20260 · 2
William A. Backus Company insiderVP & Chief Accounting Officer · last 12 Feb 20260 · 13
Daniel E. Knutson Company insiderDirector · last 11 Feb 20261 · 0
David B. Fischer Company insiderDirector · last 11 Feb 20260 · 4

Same industry

FF FutureFuelLeading+19%
IOSP InnospecLeading+15%
MEOH MethanexLeading+12%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 20259.1%
Operating profit marginFY 2025 · to 31 Dec 202520.2%
Return on capital employedFY 2025 · to 31 Dec 202513.9%
Cash conversionFY 2025 · to 31 Dec 2025140%
Research spendFY 2025 · to 31 Dec 20251.8%
Revenue growthFY 2025 · to 31 Dec 2025288%
Earnings per share growthFY 2025 · to 31 Dec 2025283%
Share count trendFY 2025 · to 6 Feb 2026-0.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$74.6M

Analyst forecasts

No analyst forecasts yet.